Xyrem gains daytime claim
Executive Summary
FDA clears Jazz Pharmaceuticals' Xyrem (sodium oxybate) for treatment of excessive daytime sleepiness in patients with narcolepsy Nov. 18. Xyrem was previously approved for cataplexy in narcolepsy patients. The firm has said that it would seek a general narcolepsy indication; cataplexy and EDS are the two primary symptoms of narcolepsy (1"The Pink Sheet" April 25, 2005, p. 26)...
You may also be interested in...
Jazz Pharma Acquires Orphan Medical; Plans Variations On Xyrem
Jazz Pharmaceuticals is likely to experiment with new formulations of the narcolepsy agent Xyrem (sodium oxybate) after acquiring Orphan Medical
More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Merck & Co. Will Manufacture J&J Vaccine, Other COVID-19 Medicines Under BARDA Deal
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: